

Jan-Patrick Stellmann

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8409316/publications.pdf>

Version: 2024-02-01

72
papers

2,578
citations

236612

25
h-index

214527

47
g-index

76
all docs

76
docs citations

76
times ranked

4332
citing authors

#	ARTICLE	IF	CITATIONS
1	Costs and Health-Related Quality of Life in Patients With NMO Spectrum Disorders and MOG-Antibody-Associated Disease. <i>Neurology</i> , 2022, 98, .	1.5	14
2	Brain grey matter perfusion in primary progressive multiple sclerosis: Mild decrease over years and regional associations with cognition and hand function. <i>European Journal of Neurology</i> , 2022, 29, 1741-1752.	1.7	5
3	Borrowing strength from adults: Transferability of AI algorithms for paediatric brain and tumour segmentation. <i>European Journal of Radiology</i> , 2022, 151, 110291.	1.2	3
4	Interleukin-6 Receptor Blockade in Treatment-Refractory MOG-IgG-Associated Disease and Neuromyelitis Optica Spectrum Disorders. <i>Neurology: Neuroimmunology and Neuroinflammation</i> , 2022, 9, .	3.1	64
5	Alterations of Microstructure and Sodium Homeostasis in Fast Amyotrophic Lateral Sclerosis Progressors: A Brain DTI and Sodium MRI Study. <i>American Journal of Neuroradiology</i> , 2022, 43, 984-990.	1.2	7
6	Heterogeneity of multiple sclerosis lesions in fast diffusional kurtosis imaging. <i>PLoS ONE</i> , 2021, 16, e0245844.	1.1	16
7	Study protocol for a randomised controlled trial of a web-based behavioural lifestyle programme for emPOWERment in early Multiple Sclerosis (POWER@MS1). <i>BMJ Open</i> , 2021, 11, e041720.	0.8	5
8	Rituximab-Induced Hypogammaglobulinemia and Infections in AQP4 and MOG Antibody-Associated Diseases. <i>Neurology: Neuroimmunology and Neuroinflammation</i> , 2021, 8, .	3.1	26
9	Delayed access to conscious processing in multiple sclerosis: Reduced cortical activation and impaired structural connectivity. <i>Human Brain Mapping</i> , 2021, 42, 3379-3395.	1.9	1
10	Pain, Depression, and Quality of Life in Neuromyelitis Optica Spectrum Disorder. <i>Neurology: Neuroimmunology and Neuroinflammation</i> , 2021, 8, .	3.1	41
11	Cognitive performance shows domain specific associations with regional cortical thickness in multiple sclerosis. <i>NeuroImage: Clinical</i> , 2021, 30, 102606.	1.4	8
12	T1 Relaxation Times in the Cortex and Thalamus Are Associated With Working Memory and Information Processing Speed in Patients With Multiple Sclerosis. <i>Frontiers in Neurology</i> , 2021, 12, 789812.	1.1	7
13	Blunted neural and psychological stress processing predicts future grey matter atrophy in multiple sclerosis. <i>Neurobiology of Stress</i> , 2020, 13, 100244.	1.9	10
14	Aerobic Exercise Induces Functional and Structural Reorganization of CNS Networks in Multiple Sclerosis: A Randomized Controlled Trial. <i>Frontiers in Human Neuroscience</i> , 2020, 14, 255.	1.0	10
15	Smartphone Accelerometry: A Smart and Reliable Measurement of Real-Life Physical Activity in Multiple Sclerosis and Healthy Individuals. <i>Frontiers in Neurology</i> , 2020, 11, 688.	1.1	15
16	Assessing the effect of an evidence-based patient online educational tool for people with multiple sclerosis called UMIMS-”understanding magnetic resonance imaging in multiple sclerosis: study protocol for a double-blind, randomized controlled trial. <i>Trials</i> , 2020, 21, 1008.	0.7	2
17	The Myelin Water Fraction Serves as a Marker for Age-Related Myelin Alterations in the Cerebral White Matter - A Multiparametric MRI Aging Study. <i>Frontiers in Neuroscience</i> , 2020, 14, 136.	1.4	38
18	Moving exercise research in multiple sclerosis forward (the MoXFo initiative): Developing consensus statements for research. <i>Multiple Sclerosis Journal</i> , 2020, 26, 1303-1308.	1.4	46

#	ARTICLE	IF	CITATIONS
19	Distinct Functional Connectivity Signatures of Impaired Social Cognition in Multiple Sclerosis. <i>Frontiers in Neurology</i> , 2020, 11, 507.	1.1	21
20	Longitudinal optic neuritis-unrelated visual evoked potential changes in NMO spectrum disorders. <i>Neurology</i> , 2020, 94, e407-e418.	1.5	36
21	Functional and structural connectivity substrates of cognitive performance in relapsing remitting multiple sclerosis with mild disability. <i>NeuroImage: Clinical</i> , 2020, 25, 102177.	1.4	24
22	COVID-19â€™White matter and globus pallidum lesions. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020, 7, .	3.1	55
23	Feasibility of a smartphone app to enhance physical activity in progressive MS: a pilot randomized controlled pilot trial over three months. <i>PeerJ</i> , 2020, 8, e9303.	0.9	13
24	Magnetic resonance imaging as a prognostic disability marker in clinically isolated syndrome: A systematic review. <i>Acta Neurologica Scandinavica</i> , 2019, 139, 18-32.	1.0	12
25	Spectrally fat-suppressed coronal 2D TSE sequences may be more sensitive than 2D STIR for the detection of hyperintense optic nerve lesions. <i>European Radiology</i> , 2019, 29, 6266-6274.	2.3	4
26	Impairment and restrictions in possibly benign multiple sclerosis. <i>Brain and Behavior</i> , 2019, 9, e01259.	1.0	12
27	Development of Cortical Lesion Volumes on Double Inversion Recovery MRI in Patients With Relapse-Onset Multiple Sclerosis. <i>Frontiers in Neurology</i> , 2019, 10, 133.	1.1	2
28	Relapse rates and long-term outcome in primary angiitis of the central nervous system. <i>Journal of Neurology</i> , 2019, 266, 1481-1489.	1.8	17
29	Emotions towards magnetic resonance imaging in people with multiple sclerosis. <i>Acta Neurologica Scandinavica</i> , 2019, 139, 497-504.	1.0	12
30	Is multiple sclerosis progression associated with the HLA-DR15 haplotype?. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2019, 5, 205521731989461.	0.5	5
31	MOG-IgG in primary and secondary chronic progressive multiple sclerosis: a multicenter study of 200 patients and review of the literature. <i>Journal of Neuroinflammation</i> , 2018, 15, 88.	3.1	52
32	Distribution of brain sodium long and short relaxation times and concentrations: a multi-echo ultra-high field ²³ Na MRI study. <i>Scientific Reports</i> , 2018, 8, 4357.	1.6	40
33	Can resistance training impact MRI outcomes in relapsing-remitting multiple sclerosis?. <i>Multiple Sclerosis Journal</i> , 2018, 24, 1356-1365.	1.4	85
34	Low clinical conversion rate in clinically isolated syndrome patients â€™ diagnostic benefit of McDonald 2010 criteria?. <i>European Journal of Neurology</i> , 2018, 25, 247.	1.7	10
35	Perceptions on the value of bodily functions in multiple sclerosis. <i>Acta Neurologica Scandinavica</i> , 2018, 137, 356-362.	1.0	71
36	A standardised frankincense extract reduces disease activity in relapsing-remitting multiple sclerosis (the SABA phase IIa trial). <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018, 89, 330-338.	0.9	23

#	ARTICLE	IF	CITATIONS
37	The use of multiparametric quantitative magnetic resonance imaging for evaluating visually assigned lesion groups in patients with multiple sclerosis. <i>Journal of Neurology</i> , 2018, 265, 127-133.	1.8	14
38	Short-term interval aerobic exercise training does not improve memory functioning in relapsing-remitting multiple sclerosis—a randomized controlled trial. <i>PeerJ</i> , 2018, 6, e6037.	0.9	28
39	Age-Related Measurements of the Myelin Water Fraction derived from 3D multi-echo GRASE reflect Myelin Content of the Cerebral White Matter. <i>Scientific Reports</i> , 2018, 8, 14991.	1.6	38
40	Apheresis therapies for NMOSD attacks. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2018, 5, e504.	3.1	173
41	Metabolomic Profiles for Primary Progressive Multiple Sclerosis Stratification and Disease Course Monitoring. <i>Frontiers in Human Neuroscience</i> , 2018, 12, 226.	1.0	47
42	Pattern of gray matter volumes related to retinal thickness and its association with cognitive function in relapsing-remitting MS. <i>Brain and Behavior</i> , 2017, 7, e00614.	1.0	23
43	No relevant impact of ambient temperature on disability measurements in a large cohort of patients with multiple sclerosis. <i>European Journal of Neurology</i> , 2017, 24, 851-857.	1.7	5
44	Immunotherapies in neuromyelitis optica spectrum disorder: efficacy and predictors of response. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2017, 88, 639-647.	0.9	123
45	Ruxolitinib treatment in a patient with neuromyelitis optica: A case report. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2017, 4, e328.	3.1	7
46	Reduced rich-club connectivity is related to disability in primary progressive MS. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2017, 4, e375.	3.1	23
47	T1 Recovery Is Predominantly Found in Black Holes and Is Associated with Clinical Improvement in Patients with Multiple Sclerosis. <i>American Journal of Neuroradiology</i> , 2017, 38, 264-269.	1.2	22
48	Influence of female sex and fertile age on neuromyelitis optica spectrum disorders. <i>Multiple Sclerosis Journal</i> , 2017, 23, 1092-1103.	1.4	60
49	Reliability of cortical lesion detection on double inversion recovery MRI applying the MAGNIMS-Criteria in multiple sclerosis patients within a 16-months period. <i>PLoS ONE</i> , 2017, 12, e0172923.	1.1	16
50	T1w dark blood imaging improves detection of contrast enhancing lesions in multiple sclerosis. <i>PLoS ONE</i> , 2017, 12, e0183099.	1.1	5
51	Fampridine and real-life walking in multiple sclerosis: Low predictive value of clinical test for habitual short-term changes. <i>Journal of the Neurological Sciences</i> , 2016, 368, 318-325.	0.3	13
52	Novel multiple sclerosis susceptibility loci implicated in epigenetic regulation. <i>Science Advances</i> , 2016, 2, e1501678.	4.7	133
53	Neuromyelitis optica: Evaluation of 871 attacks and 1,153 treatment courses. <i>Annals of Neurology</i> , 2016, 79, 206-216.	2.8	315
54	“History had taken such a large piece out of my life” Neuroscientist refugees from Hamburg during National Socialism. <i>Journal of the History of the Neurosciences</i> , 2016, 25, 275-298.	0.1	9

#	ARTICLE	IF	CITATIONS
55	Improved Lesion Detection by Using Axial T2-Weighted MRI with Full Spinal Cord Coverage in Multiple Sclerosis. <i>American Journal of Neuroradiology</i> , 2016, 37, 963-969.	1.2	18
56	Chronic T2 Lesions in Multiple Sclerosis are Heterogeneous Regarding Phase MR Imaging. <i>Clinical Neuroradiology</i> , 2016, 26, 457-464.	1.0	9
57	Heterogeneity of Multiple Sclerosis Lesions in Multislice Myelin Water Imaging. <i>PLoS ONE</i> , 2016, 11, e0151496.	1.1	59
58	Short-term MRI measurements as predictors of EDSS progression in relapsing-remitting multiple sclerosis: grey matter atrophy but not lesions are predictive in a real-life setting. <i>PeerJ</i> , 2016, 4, e2442.	0.9	14
59	Successful Replication of GWAS Hits for Multiple Sclerosis in 10,000 Germans Using the Exome Array. <i>Genetic Epidemiology</i> , 2015, 39, 601-608.	0.6	15
60	Regression to the Mean and Predictors of MRI Disease Activity in RRMS Placebo Cohorts - Is There a Place for Baseline-to-Treatment Studies in MS?. <i>PLoS ONE</i> , 2015, 10, e0116559.	1.1	11
61	Ecological Validity of Walking Capacity Tests in Multiple Sclerosis. <i>PLoS ONE</i> , 2015, 10, e0123822.	1.1	55
62	T1- Thresholds in Black Holes Increase Clinical-Radiological Correlation in Multiple Sclerosis Patients. <i>PLoS ONE</i> , 2015, 10, e0144693.	1.1	34
63	Magnetic Resonance Imaging in Multiple Sclerosis – Patients' Experiences, Information Interests and Responses to an Education Programme. <i>PLoS ONE</i> , 2014, 9, e113252.	1.1	18
64	Treating Progressive Multifocal Leukoencephalopathy With Interleukin 7 and Vaccination With JC Virus Capsid Protein VP1. <i>Clinical Infectious Diseases</i> , 2014, 59, 1588-1592.	2.9	64
65	A 3meter Timed Tandem Walk is an early marker of motor and cerebellar impairment in fully ambulatory MS patients. <i>Journal of the Neurological Sciences</i> , 2014, 346, 99-106.	0.3	12
66	Validating Predictors of Disease Progression in a Large Cohort of Primary-Progressive Multiple Sclerosis Based on a Systematic Literature Review. <i>PLoS ONE</i> , 2014, 9, e92761.	1.1	35
67	Comparison of patient-reported outcome measures in multiple sclerosis. <i>Acta Neurologica Scandinavica</i> , 2013, 128, 114-121.	1.0	43
68	Antigen-Specific Tolerance by Autologous Myelin Peptide–Coupled Cells: A Phase 1 Trial in Multiple Sclerosis. <i>Science Translational Medicine</i> , 2013, 5, 188ra75.	5.8	262
69	Long-term treatment risks in multiple sclerosis: risk knowledge and risk perception in a large cohort of mitoxantrone-treated patients. <i>Multiple Sclerosis Journal</i> , 2013, 19, 920-925.	1.4	12
70	Prognostic Risk Estimates of Patients with Multiple Sclerosis and Their Physicians: Comparison to an Online Analytical Risk Counseling Tool. <i>PLoS ONE</i> , 2013, 8, e59042.	1.1	13
71	Placebo Cohorts in Phase-3 MS Treatment Trials – Predictors for On-Trial Disease Activity 1990-2010 Based on a Meta-Analysis and Individual Case Data. <i>PLoS ONE</i> , 2012, 7, e50347.	1.1	22
72	1.318 Malignant neuroleptic syndrome in a case of acute extrapontine myelinolysis. <i>Parkinsonism and Related Disorders</i> , 2007, 13, S81.	1.1	0